Daniel A Luedtke

559 total citations
10 papers, 436 citations indexed

About

Daniel A Luedtke is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Daniel A Luedtke has authored 10 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Immunology. Recurrent topics in Daniel A Luedtke's work include Cell death mechanisms and regulation (5 papers), DNA Repair Mechanisms (2 papers) and RNA Interference and Gene Delivery (2 papers). Daniel A Luedtke is often cited by papers focused on Cell death mechanisms and regulation (5 papers), DNA Repair Mechanisms (2 papers) and RNA Interference and Gene Delivery (2 papers). Daniel A Luedtke collaborates with scholars based in United States, China and Netherlands. Daniel A Luedtke's co-authors include Holly Edwards, Yubin Ge, Jeffrey W. Taub, Tristan Knight, Hai Lin, Shuang Liu, Yongwei Su, Jianyun Zhao, Kang Chen and Yihang Pan and has published in prestigious journals such as Blood, Scientific Reports and Biochemical Pharmacology.

In The Last Decade

Daniel A Luedtke

10 papers receiving 433 citations

Peers

Countries citing papers authored by Daniel A Luedtke

Since Specialization

Citations

This map shows the geographic impact of Daniel A Luedtke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A Luedtke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A Luedtke more than expected).

Fields of papers citing papers by Daniel A Luedtke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A Luedtke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A Luedtke. The network helps show where Daniel A Luedtke may publish in the future.

Co-authorship network of co-authors of Daniel A Luedtke

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A Luedtke. A scholar is included among the top collaborators of Daniel A Luedtke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A Luedtke. Daniel A Luedtke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML 2022 ·Blood ·Jan S. Rosenbaum, Scott B. Hoyt, (unknown), Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski	2
2	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies 2021 ·European Journal of Cancer ·Kaylee M. Keller, Sonja Krausert, (unknown), Daniel A Luedtke, Jan Köster, (unknown), Ana Isabel Enríquez Rodríguez, Sander R. van Hooff, Damian Stichel, M. Emmy M. Dolman, Gilles Vassal, Stefan M. Pfister, Hubert Caron, Louis F. Stancato, Jan J. Molenaar, Natalie Jäger, Marcel Kool	12
3	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia 2020 ·Signal Transduction and Targeted Therapy ·Daniel A Luedtke, Yongwei Su, Jun Ma, Xinyu Li, Steven Buck, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Hai Lin, Jeffrey W. Taub, Yubin Ge	50
4	A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics 2019 ·Biochemical Pharmacology ·Tristan Knight, Daniel A Luedtke, Holly Edwards, Jeffrey W. Taub, Yubin Ge	131
5	Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1 2018 ·Journal of Cellular and Molecular Medicine ·Daniel A Luedtke, Yongwei Su, Shuang Liu, Holly Edwards, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge	46
6	H₂O₂/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells 2018 ·ACS Medicinal Chemistry Letters ·Yi Liao, Liping Xu, (unknown), Holly Edwards, Daniel A Luedtke, Yubin Ge, Zhihui Qin	40
7	Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia 2018 ·Blood ·Daniel A Luedtke, Yongwei Su, Holly Edwards, Lisa Polin, Juiwanna Kushner, (unknown), Hai Lin, Jeffrey W. Taub, Yubin Ge	2
8	Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia 2017 ·Blood ·Daniel A Luedtke, Yongwei Su, Holly Edwards, Hai Lin, Jeffrey W. Taub, Yubin Ge	3
9	Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells 2017 ·Signal Transduction and Targeted Therapy ·Daniel A Luedtke, Xiaojia Niu, Yihang Pan, Jianyun Zhao, Shuang Liu, Holly Edwards, Kang Chen, Hai Lin, Jeffrey W. Taub, Yubin Ge	101
10	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells 2017 ·Scientific Reports ·Jun Ma, Xinyu Li, Yongwei Su, Jianyun Zhao, Daniel A Luedtke, (unknown), Holly Edwards, Guan Wang, Zhihong Wang, Roland Chu, Jeffrey W. Taub, Hai Lin, Yue Wang, Yubin Ge	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact